Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AT-301
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Atossa Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study
Details : The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.
Product Name : AT-301
Product Type : Vaccine
Upfront Cash : Undisclosed
July 22, 2020
Lead Product(s) : AT-301
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Atossa Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
